A Phase 1 Open-label Multicenter Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of IGM-2323 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphomas

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
  • Age: Between 18 - 90 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Histologically confirmed follicular lymphoma (FL) Grades 1-3a, or Grade 3b or histologically confirmed diffuse large B-cell lymphoma (DLBCL) or trFL or additional CD20-positive NHL histologies (e.g., marginal zone lymphoma (MZL) and marginal zone lymphoma (MCL)) may be allowed with Medical Monitor approval during the Dose-Escalation Phase of the study. 2) Relapsed or refractory to at least 2 prior systemic treatment regimens (must include anti-CD20 based chemo-immunotherapy regimen).

You may not be eligible for this study if the following are true:

  • 1) Known Double/Triple Hit Lymphoma (MYC, and BCL-2 or BCL-6 translocation). 2) Chronic Lymphocytic Leukemia (CLL), or Richters transformation.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.